Join us at Curecast
On November 6, Katie Couric, leading experts, and advocates will share how Project Cure CRC is transforming research and advancing care.


A colorectal cancer diagnosis can change your life in countless ways — physically, emotionally, and socially. At the Colorectal Cancer Alliance, we’re dedicated to listening to patients and survivors so we can offer the meaningful support they need. Recently, we launched a survey to better understand the biggest unmet needs facing the colorectal cancer (CRC) community. Our findings were presented at the ASCO Gastrointestinal Cancers Symposium last week.
What We Found
Why It Matters
These findings shed light on the depth of psychosocial and physical needs faced by CRC patients and survivors. We now have tangible data showing that life after diagnosis can be isolating and that support is needed far beyond the doctor’s office.
Armed with these insights, the Alliance is committed to creating new support programs, resources, and clinical strategies to better serve our community. Whether it’s connecting you to a Buddy through our peer support program or offering guidance through treatment and beyond, we want to ensure no one faces colorectal cancer alone.
“We believe these survey results will spark meaningful changes in CRC care and provide renewed hope,” said Kim Newcomer, an Alliance staff member who presented posters at ASCO GI. “If you’re a part of our community, thank you. Your voice helps shape the future of support and care for everyone impacted by CRC.”

When Kate Shin’s mother faced rectal cancer, clinical trials gave them precious time together. Now, Kate shares her story to encourage access to screening and innovative care, including clinical trials.

The Alliance's Project Cure CRC announces $1.3 million in new research grants — bringing total funding to nearly $12 million — to drive breakthroughs in colorectal cancer care and address critical research gaps.

The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.